Financial Results for the quarter ended on June 30, 2026.

MEDICAMEN Biotech Limited I i |3 Regd. & Corp. Office: Tel.: 011 - 47589500-51 (50 Lines), - E-mail: infol Web: www.med! 3 (INDIA CIN No.: L7489 Ref: STEX/OUTCOME/2026-27 Date: 14.08.2026 rééE Limited - National Stock Exchange of India Limited | 25th Floor Exchange Plaza, C-1, Phiroze Jeejebhoy Towers Block - G Bandra Kurla Dalal Street, Mumbai 400 001 Complex Bandra (East) Mumb-a 40i0 051 | BSE Code-531146 | NSE Code: MEDICAMEQ Sub.: Outcome of Board Meeting Dear Sir, We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2026. Pursuant to Regulation 30 & 33 read with Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following: a) Statement showing the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026 as Annexure-A; and b) Limited Review Report on the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026 as Annexure- Further, the Board of Directors at their meeting considered, approved and took note of the following matters: c) Approval of Draft Annual Report for the Financial Year 2025-26 The Board approved the draft Annual Report of the Company for the financial year 2025-26. d) Approval of Draft Cost Audit Report for the Financial Year 2025-26 The Board approved the draft Cost Audit Report of the Company for the financial year 2025-26. PARUL Ditallysigned by PARUL CHOUDH choubtry Date: 2026.08.14 ARY 15:19:50 +05'30° Works: Unit tor-64, Unitit MEDICAMEN Biotech Limited I I'B Corp. Office: o Tel.: 011 - 47559501 E-mail: info@medi NDIA: Web: www.medicar CIN No.: L74899D! d) 33rd Annual General Meeting The Board approved that the 33rd Annual General Meeting of the Company will be held on Saturday, September 26, 2026 at 12.00 Noon through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) facility. Pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Saturday, September 19, 2026 as the cut-off date for the purpose of determining the eligibility of shareholders holding shares either in physical or dematerialized form to cast their votes electronically. The e- voting period shall commence from Wednesday, September 23, 2026 and end on Friday, September 25, 2026. e) Closure of Register of Members and Share Transfer Books In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the closure of the Register of Members and other Transfer Books of the Company from Saturday, September 19, 2026 to Friday, September 25, 2026 (both days inclusive), in connection with the proposed payment of Final Dividend @ 10% i.e. Re. 1/- per Equity Share, subject to approval of the members at the forthcoming Annual General Meeting. f) Taking note of notices/communications received from Stock Exchanges The Board took note of the notices/communications received from BSE Limited and National Stock Exchange of India Limited (Copy enclosed as Annexure-C) in respect of non-compliance/compliance-related matters under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable Standard Operating Procedure/penal provisions prescribed by the Stock Exchanges. The Board specifically took note of the notice received from BSE Limited dated May 27, 2026, regarding fines pursuant to the applicable SEBI Master Circular relating to penal action for non-compliance, wherein the Exchange had observed non- compliance with Regulation 19(1)/19(2) of the SEBI (LODR) Regulations, 2015 relating to inclusion of an Executive Member instead of Non-Executive Member in the constitution of the Nomination and Remuneration Committee, and levied a basic fine of 94,000 plus GST of 16,920, aggregating to X1,10,920. The Board also took note of the communication received from National Stock Exchange of India Limited in relation to listing fine fees for non-compliance with the applicable requirements, involving a basic fine of %9 IGST of 16,920, aggregating to X1,10,920. PARUL Digitaly signed by PARUL CHOUDH croupsiaay Date: 2026.08.14 ARY 15:20:08 40530 MEDICAMEN Biotech Limited Regd. & Corp. Office The payment has been made to both the exchanges on June 02, 2026. The Board considered the contents of the aforesaid communications and directed the concerned officials of the Company to take necessary corrective and compliance measures and to ensure strict adherence to the applicable provisions of the SEBI (LODR) Regulations, 2015 and the requirements of the Stock Exchanges. The Board further directed that the necessary actions in respect of the matters referred to in the aforesaid communications be taken within the stipulated timelines and that the requisite responses/remittance/compliance details, wherever applicable, be submitted to the respective Stock Exchanges. Please note that the reports of Auditors are with unmodified opinion with respect to the Unaudited Financial Results of the Company for the quarter ended June 30, 2026. The meeting of the Board of Directors commenced at 02.00 p.m. and concluded at 03.15 p.m. The Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026, as approved by the Board, will also be available on the Company’s website www.medicamen.com. This is for your information and records. Thanking You, Yours faithfully, PARUL :‘;Qsz%iigned CHOUDH cHoubHary Paru(audh Date:2026.08.14 ARY 15:20:29 +05'30' Company Secret: ACS44157 Annexure-4 MEDICAMEN BIOTECH LIMITED I Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 CIN : L74899DL 1993PLCO56594 E-mail : cs@medicamen.com, Website: www.medicamen.com PART | Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June'2026 _ . Standalone Consolidated Three Month Period Ended Year Ended Three Month Period Ended Year Ended Particulars 30.06.2026 | 31.03.2026 | 30062025 | 31.03.2026 | 30.06.2026 | 31.03.2026 | 30.06.2025 | 31032026 o Unaudited | Audited | Unaudited | Audited | Unaudited Audited Unaudited | Audited 1 [Income from operations (2} Net Sales / Income from operations 4,385.27 5,468.08 3,844.90 17,884.58 4,789.69 6,064.66 4,304.48 19,776.97 {0) Other Income 86.16 172.63 47.03 310.43 86.16 173.52 47.03 311.32 (c) Total Revenue 4,471.43 5,640.71 3,891.93 18,195.01 4,875.85 6,238.18 4,351.50 20,088.29 2 |Expenses a b) ) C Po us rt c ho af s M ea t ofe r Gia ol o dC so n Trs au dm ee dd 2,207.92 2,543.12 2,337.78 9,181.38 2,261.07 2,609.23 2,459.77 9,434.81 ©) Changes in inventory of Finished Goods and Work in Progress (114499..0055)) 610,a 1 (118888..44¢9 ) 74422 38 ( 11 44 99 .. 00 55 ,) 61 0.41 ( 11 88 88 .. 44 ¢9 ) 742 2.. 38 d) Employees Benefits Expenses 62233 524.03 530553 227867 93138 930.91 809.03 3,469.31 e} Finance Cost 63.94 59.89 56.24 278.45 82.88 38.30 115.34 349.74 f) Depreciation and Amortisation Expenses 174.38 172.50 177.30 705.87 178.69 173.32 180.13 721.85 8) Other expenses 1,226.12 1,277.81 711.65 3,853.49 1,313.70 1,361.03 762.63 4,171.75 Total i Expenses ! 4,145.64 5,287.76 3,675.00 17,040.23 4,618.68 5,732.21 4,138.41 18,889.85 3 Zm'z'"/""ss) before ExceptionalliemsifiTox 325.79 352.95 216.94 1,158.78 257.17 505.97 213.09 1,198.44 4 v| eE ax rc sep tional items (commeTaxr Ecxpeinsaes Reloteod = B 5 ;’3"";')/(“’”’ heforelExtra Ordinary tamsi&Téx 32579 352,95 216.94 1,154.78 2577 505.97 213.09 1,198.4 6 |TaxExpenses Current Year 83,01 65.28 EX3 35283 83,01 65.08 5696 35083 MDeA fT er C rr ee dd i Tt a xE n Lt ii abt il le im tye nt o1- ) (95= 4 ) [@D) {@051- ) {10.2 42) (o- ) (3- . 97) 36.0» 3 ] p [ T o[o pFt eea rtl ar tuT iia" onx E (x / -p e s 6n ste l or ilo l fom Com. in g 27 53 2. 61 90 295 75 .. 27 24 165 33 .. 62 68 92 [Showing first 8,000 characters — download PDF for full document]